Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
CSPC PharmaCeutiCal GrouP limited ͩᖹණྠϞࠢʮ̡
(Incorporated in Hong Kong under the Companies Ordinance)
(Stock Code: 1093)
iNSide iNFormatioN
PriNCiPal FiNaNCial iNFormatioN oF CSPC iNNoVatioN PharmaCeutiCal Co., ltd.
For the Year eNded 31 deCember 2020
This announcement is made by CSPC Pharmaceutical Group Limited (the "Company") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
CSPC Innovation Pharmaceutical Co., Ltd. ("CSPC XNW") is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC XNW has published its 2020 Annual Report ("annual report") on the information disclosure webpage of Shenzhen Stock Exchange's website athttp://www.szse.cn/disclosure/listed/notice/index.html.
The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendices of this announcement (the "appendices") which set out the principal financial information of CSPC XNW prepared in accordance with the PRC Accounting Standard for Business Enterprises for the year ended 31 December 2020.
Please note that the information in the Appendices is an extract of the Annual Report in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.
By Order of the Board
CSPC Pharmaceutical Group limited
Cai dongchen
Chairman
Hong Kong, 4 March 2021
As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Dr. YU Jinming, Mr. CHEN Chuan, Prof. WANG Hongguang and Mr. AU Chun Kwok Alan as independent non-executive directors.
aPPeNdiX i
PriNCiPal aCCouNtiNG data aNd FiNaNCial iNdiCatorS
Unit: RMB (Yuan)
2020 | 2019 | increase/decrease compared with the last year | 2018 | |
Revenue | 1,317,414,122.08 | 1,256,502,359.88 | 4.85% | 1,240,098,691.33 |
Net profit attributable to listed company's shareholders | 299,835,756.44 | 273,197,126.61 | 9.75% | 223,840,143.77 |
Net profit attributable to listed company's shareholders less the non-recurring gain/loss | 263,188,500.07 | 238,465,715.95 | 10.37% | 212,837,369.00 |
Net cash flows arising from operating activities | 349,071,664.26 | 315,384,186.07 | 10.68% | 159,727,619.61 |
Basic earnings per share (Yuan/ share) | 0.714 | 0.694 | 2.88% | 0.711 |
Diluted earnings per share (Yuan/ share) | 0.714 | 0.694 | 2.88% | 0.711 |
Weighted average return on net assets | 11.82% | 13.77% | -1.95% | 25.47% |
end of 2020 | end of 2019 | increase/decrease compared with the end of last year | end of 2018 | |
Total assets | 2,954,902,756.59 | 2,852,373,126.14 | 3.59% | 1,390,799,205.46 |
Net assets attributable to listed company's shareholders | 2,678,111,938.23 | 2,406,399,708.49 | 11.29% | 990,767,205.16 |
aPPeNdiX ii
NoN-reCurriNG GaiN/loSS itemS aNd amouNtS
Unit: RMB (Yuan)
items | amounts in 2020 | amounts in 2019 | amounts in 2018 | description |
Gain/loss from disposal of non-current assets (including the part offset with the provision for impairment of assets) | -430,725.37 | -1,993,792.46 | -299,607.08 | |
Government grants recognised in profit or loss of current period (excluding those closely related to the company's business and granted under the State's policies according to certain quota of amount or volume) | 23,098,080.33 | 23,815,570.94 | 14,521,070.87 | |
Gain/loss from entrusted investments or assets management | 22,978,112.40 | 21,808,271.60 | ||
Non-operating income and expenses other than the above items | -435,965.16 | 71,723.10 | 1,145,461.02 | |
Less: Impact of income tax | 8,567,097.89 | 8,910,323.87 | 3,724,199.83 | |
Impact of minority interests (after tax) | -4,852.06 | 60,038.65 | 639,950.21 | |
Total | 36,647,256.37 | 34,731,410.66 | 11,002,774.77 | - |
aPPeNdiX iii
SiGNiFiCaNt ChaNGeS iN aSSetS
Unit: RMB (Yuan)
major assets | description on significant changes |
Equity assets | No significant changes |
Fixed assets | No significant changes |
Intangible assets | No significant changes |
Construction in progress | Closing balance is RMB154,828,065.57 and opening balance is RMB108,134,496.09, representing an increase of 43.18%, mainly due to the increase in the investment in investment projects. |
Bank balances and cash | Closing balance is RMB1,138,744,787.20 and opening balance is RMB475,141,505.60, representing an increase of 139.66%, mainly due to the growth in the business scale of the Company, increase in sales receipts and redemption upon maturity of cash management using idle proceeds. |
Financial assets held for trading | Closing balance is RMB321,943,412.99 and opening balance is RMB960,086,125.04, representing a decrease of 66.47%, mainly due to the redemption upon maturity of cash management using idle proceeds. |
Long-term equity investments | Closing balance is RMB235,874,486.64 and opening balance is RMB156,285,100.38, representing an increase of 50.93%, mainly due to the acquisition of 9.77% interest in Guoxinhuijin held by NBP Pharmaceutical. |
Other current assets | Closing balance is RMB26,031,698.78 and opening balance is RMB14,881,297.50, representing an increase of 74.93%, mainly due to the increase in deductible value-added tax. |
Attachments
- Original document
- Permalink
Disclaimer
CSPC Pharmaceutical Group Ltd. published this content on 04 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2021 12:40:04 UTC.